Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
Boundless Bio, Inc. logo

NASDAQ · BOLD

Boundless Bio, Inc.

Healthcare · Biotechnology

$2.83

Down-$0.01 (-0.35%)

Updated Sep 12, 2026, 5:21 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
25.74M
P/E ratio
-0.4
Dividend yield
0.00%
52-week range
$1.07 – $3.16
Volume
63.84K
Avg. volume
159.75K

Price performance

BOLD price history

1M range · 20 trading sessions · Daily adjusted prices

BOLD closed at $2.83 after 20 trading sessions, up 0.00% for the selected period.

Last close
$2.83
Period change
+0.00%
Period low
$2.81
Period high
$3.00
Daily close
View OHLC price history
BOLD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$2.85$2.85$2.81$2.8363.84K
Sep 10, 2026$2.85$2.87$2.82$2.8428.65K
Sep 9, 2026$2.86$2.8781$2.83$2.8548.82K
Sep 8, 2026$2.87$2.94$2.76$2.86168K
Sep 4, 2026$2.87$2.89$2.86$2.8720K
Sep 3, 2026$2.90$2.94$2.85$2.8772.44K
Sep 2, 2026$2.89$2.91$2.85$2.8981.53K
Sep 1, 2026$2.81$2.905$2.805$2.89146.03K
Aug 31, 2026$2.81$2.94$2.80$2.81103.24K
Aug 28, 2026$2.82$2.86$2.80$2.8375.54K
Aug 27, 2026$2.91$2.99$2.86$2.8646.67K
Aug 26, 2026$2.98$3.04$2.90$2.915158.8K
Aug 25, 2026$2.96$3.00$2.93$2.9441.26K
Aug 24, 2026$3.05$3.1636$2.905$2.96118.48K
Aug 21, 2026$2.91$3.02$2.91$3.00157.16K
Aug 20, 2026$2.84$3.01$2.84$2.90218.74K
Aug 19, 2026$2.89$2.935$2.80$2.8695.55K
Aug 18, 2026$2.83$2.95$2.83$2.86145K
Aug 17, 2026$2.77$2.885$2.712$2.83139.13K
Aug 14, 2026$2.78$2.84$2.735$2.83108.96K

Latest BOLD news

The latest Smart Investors Daily articles mentioning BOLD.

Stock researchCompany · Overview

BOLD research

Overview

Company profile and research snapshot.

Company profile

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.06
Implied upside
—
Analysts
—
BOLD recent ratings
DateFirmRatingTarget
Aug 11, 2025HC Wainwright & Co.Buy—
Jun 2, 2025HC Wainwright & Co.Buy—
May 28, 2025Leerink PartnersMarket Perform—
Dec 13, 2024GuggenheimNeutral—
Apr 22, 2024Leerink PartnersOutperform—
Open full forecast

News briefing

Generated Sep 11, 2026, 9:09 PM

Why Is BOLD Slightly Down Today?

Boundless Bio (BOLD) declined marginally by $0.01 (0.35%) today with minimal trading activity driving the slight pullback. The modest price movement appears disconnected from company-specific catalysts, suggesting broader market conditions or low volume trading may be responsible for the modest decline.

    Bottom line: BOLD's marginal 0.35% decline today appears driven by low trading volume and sector-wide headwinds rather than company-specific negative news. Investors should view this modest pullback as a potential entry opportunity if the company's pipeline prospects remain intact, while remaining vigilant for clinical trial updates or partnership announcements that could provide meaningful upside catalysts.

    Yahoo · Sep 9, 2026

    Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

    Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior Scientific Advisor SAN DIEGO and SEATTLE and SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a clinical-stage

    Benzinga · Sep 9, 2026

    Callio Therapeutics Appoints Zachary Hornby As CEO

    Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancerPiers Ingram, PhD, Co-Founder, transitions to Senior Advisor and

    Benzinga · Aug 10, 2026

    Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate

    Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.61) by 73.77 percent. This is a 51.43 percent decrease over losses of $(0.70) per share from

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By